Biolife Solutions (BLFS) Cash & Equivalents (2010 - 2026)

Biolife Solutions (BLFS) has reported Cash & Equivalents for 17 consecutive years, with $22.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 65.91% year-over-year to $22.8 million; the TTM figure through Mar 2026 stood at $22.8 million (down 65.91% YoY), while the FY2025 annual figure was $33.0 million, down 63.91% from the prior year.
• Cash & Equivalents eased to $22.8 million in Q1 2026 per BLFS's latest filing, from $33.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $91.5 million in Q4 2024 and bottomed at $19.1 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $33.5 million across 5 years, with a median of $27.0 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 72.17% — and 2024, when it jumped 228.14%.
• Biolife Solutions' Cash & Equivalents stood at $19.4 million in 2022, then jumped by 43.48% to $27.9 million in 2023, then surged by 228.14% to $91.5 million in 2024, then tumbled by 63.91% to $33.0 million in 2025, then plunged by 30.92% to $22.8 million in 2026.
• Business Quant data shows BLFS's Cash & Equivalents at $22.8 million in Q1 2026, $33.0 million in Q4 2025, and $29.5 million in Q3 2025.